A Phase II Study of Neoadjuvant Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NeoPlus
- 04 Jun 2024 Updated results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting, as per presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (As of Dec 2022, n=19) presented at the 59th Annual Meeting of the American Society of Clinical Oncology